Offshoring to China: What should your model be?

BioPharm International

Volumn 19, Issue 12, 2006, Pages 48-52

  Denault, Jean Francois ^a  

^a Impacts Solutions   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICINE; BIOTECHNOLOGY; CHINA; COMMERCIAL PHENOMENA; COST EFFECTIVENESS ANALYSIS; FINANCIAL MANAGEMENT; HUMAN; INDUSTRY; INVESTMENT; JOINT VENTURE; MARKETING; MEDICAL TECHNOLOGY; POLICY; PRACTICE GUIDELINE; REVIEW; SCIENTIST;

EID: 33846197481     PISSN: 1542166X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. Miller J. All eyes on Asia: Manufacturing in Asia, China and India. BioPharm Int. 2005 18(9); 28-30.
2. Jones Lang Lasalle. Offshoring market in China expected to grow further. 2004. Chicago: Jones Lang Lasalle. Available from: www.joneslanglasalle. com.cn/en-gb/news/2004/9_September_2004.htm
3. Dowd Greene C. India and China: Emerging generic strategies. GPHA API 2006 Meeting; 2006 Mar 21; New York, NY.
4. Goodall S, Janssens B, Wagner K, Wong J, Woods W, Yeh M. The promise of the East: India and China as R&D options, BIOEntrepreneur. Published online at www.nature.com/bioent. 2006 Jul; doi:10.1038/bioent910.
5. Boston Consulting Group. A game plan for China. Rising to the productivity challenge in biopharma R&D. 2005 Dec. 114